IBDEI1NK ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,27650,2)
 ;;=^5001550
 ;;^UTILITY(U,$J,358.3,27651,0)
 ;;=C82.90^^132^1320^73
 ;;^UTILITY(U,$J,358.3,27651,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27651,1,3,0)
 ;;=3^Follicular Lymphoma Unspec,Unspec Site
 ;;^UTILITY(U,$J,358.3,27651,1,4,0)
 ;;=4^C82.90
 ;;^UTILITY(U,$J,358.3,27651,2)
 ;;=^5001541
 ;;^UTILITY(U,$J,358.3,27652,0)
 ;;=R59.1^^132^1320^58
 ;;^UTILITY(U,$J,358.3,27652,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27652,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Generalized
 ;;^UTILITY(U,$J,358.3,27652,1,4,0)
 ;;=4^R59.1
 ;;^UTILITY(U,$J,358.3,27652,2)
 ;;=^5019530
 ;;^UTILITY(U,$J,358.3,27653,0)
 ;;=C91.40^^132^1320^77
 ;;^UTILITY(U,$J,358.3,27653,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27653,1,3,0)
 ;;=3^Hairy Cell Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,27653,1,4,0)
 ;;=4^C91.40
 ;;^UTILITY(U,$J,358.3,27653,2)
 ;;=^5001771
 ;;^UTILITY(U,$J,358.3,27654,0)
 ;;=C91.42^^132^1320^75
 ;;^UTILITY(U,$J,358.3,27654,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27654,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,27654,1,4,0)
 ;;=4^C91.42
 ;;^UTILITY(U,$J,358.3,27654,2)
 ;;=^5001773
 ;;^UTILITY(U,$J,358.3,27655,0)
 ;;=C91.41^^132^1320^76
 ;;^UTILITY(U,$J,358.3,27655,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27655,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,27655,1,4,0)
 ;;=4^C91.41
 ;;^UTILITY(U,$J,358.3,27655,2)
 ;;=^5001772
 ;;^UTILITY(U,$J,358.3,27656,0)
 ;;=D57.01^^132^1320^78
 ;;^UTILITY(U,$J,358.3,27656,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27656,1,3,0)
 ;;=3^Hb-SS Disease w/ Acute Chest Syndrome
 ;;^UTILITY(U,$J,358.3,27656,1,4,0)
 ;;=4^D57.01
 ;;^UTILITY(U,$J,358.3,27656,2)
 ;;=^5002307
 ;;^UTILITY(U,$J,358.3,27657,0)
 ;;=D57.00^^132^1320^79
 ;;^UTILITY(U,$J,358.3,27657,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27657,1,3,0)
 ;;=3^Hb-SS Disease w/ Crisis,Unspec
 ;;^UTILITY(U,$J,358.3,27657,1,4,0)
 ;;=4^D57.00
 ;;^UTILITY(U,$J,358.3,27657,2)
 ;;=^5002306
 ;;^UTILITY(U,$J,358.3,27658,0)
 ;;=D57.02^^132^1320^80
 ;;^UTILITY(U,$J,358.3,27658,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27658,1,3,0)
 ;;=3^Hb-SS Disease w/ Splenic Sequestration
 ;;^UTILITY(U,$J,358.3,27658,1,4,0)
 ;;=4^D57.02
 ;;^UTILITY(U,$J,358.3,27658,2)
 ;;=^5002308
 ;;^UTILITY(U,$J,358.3,27659,0)
 ;;=D68.32^^132^1320^82
 ;;^UTILITY(U,$J,358.3,27659,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27659,1,3,0)
 ;;=3^Hemorrhagic Disorder d/t Extrinsic Circulating Anticoagulants
 ;;^UTILITY(U,$J,358.3,27659,1,4,0)
 ;;=4^D68.32
 ;;^UTILITY(U,$J,358.3,27659,2)
 ;;=^5002357
 ;;^UTILITY(U,$J,358.3,27660,0)
 ;;=C22.2^^132^1320^83
 ;;^UTILITY(U,$J,358.3,27660,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27660,1,3,0)
 ;;=3^Hepatoblastoma
 ;;^UTILITY(U,$J,358.3,27660,1,4,0)
 ;;=4^C22.2
 ;;^UTILITY(U,$J,358.3,27660,2)
 ;;=^5000935
 ;;^UTILITY(U,$J,358.3,27661,0)
 ;;=D58.9^^132^1320^85
 ;;^UTILITY(U,$J,358.3,27661,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27661,1,3,0)
 ;;=3^Hereditary Hemolytic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,27661,1,4,0)
 ;;=4^D58.9
 ;;^UTILITY(U,$J,358.3,27661,2)
 ;;=^5002322
 ;;^UTILITY(U,$J,358.3,27662,0)
 ;;=C81.99^^132^1320^86
 ;;^UTILITY(U,$J,358.3,27662,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27662,1,3,0)
 ;;=3^Hodgkin Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,27662,1,4,0)
 ;;=4^C81.99
 ;;^UTILITY(U,$J,358.3,27662,2)
 ;;=^5001460
 ;;^UTILITY(U,$J,358.3,27663,0)
 ;;=C81.90^^132^1320^87
 ;;^UTILITY(U,$J,358.3,27663,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27663,1,3,0)
 ;;=3^Hodgkin Lymphoma,Unspec Site
